Lifecore Biomedical Relocates Principal Executive Offices
Ticker: LFCR · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1005286
| Field | Detail |
|---|---|
| Company | Lifecore Biomedical, Inc. \De\ (LFCR) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: office-relocation, administrative
Related Tickers: LFCR
TL;DR
Lifecore Biomedical moved its main office to Chaska, MN, effective Sept 11.
AI Summary
On September 11, 2024, Lifecore Biomedical, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 3515 Lyman Boulevard, Chaska, Minnesota 55318. This move was effective as of September 11, 2024.
Why It Matters
A change in principal executive offices can signal operational shifts or strategic realignments within the company.
Risk Assessment
Risk Level: low — This filing reports a change of address for the company's principal executive offices, which is a routine administrative event.
Key Players & Entities
- Lifecore Biomedical, Inc. (company) — Registrant
- 3515 Lyman Boulevard, Chaska, Minnesota 55318 (location) — New principal executive offices
- September 11, 2024 (date) — Effective date of the office change
FAQ
What is the new address for Lifecore Biomedical, Inc.'s principal executive offices?
The new address is 3515 Lyman Boulevard, Chaska, Minnesota 55318.
When did the change in principal executive offices become effective?
The change became effective on September 11, 2024.
What is the filing date of this 8-K report?
The filing date is September 12, 2024.
What is the state of incorporation for Lifecore Biomedical, Inc.?
Lifecore Biomedical, Inc. is incorporated in Delaware.
What was Lifecore Biomedical, Inc.'s former company name?
Lifecore Biomedical, Inc.'s former company name was Landec Corp.
Filing Stats: 662 words · 3 min read · ~2 pages · Grade level 14.4 · Accepted 2024-09-12 07:09:10
Filing Documents
- lndc-20240911.htm (8-K) — 26KB
- 0001005286-24-000130.txt ( ) — 147KB
- lndc-20240911.xsd (EX-101.SCH) — 2KB
- lndc-20240911_lab.xml (EX-101.LAB) — 21KB
- lndc-20240911_pre.xml (EX-101.PRE) — 12KB
- lndc-20240911_htm.xml (XML) — 3KB
01 Other Items
Item 8.01 Other Items On September 11, 2024, Lifecore Biomedical, Inc. (the "Company") received a notice from the Nasdaq Stock Market, LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5250(c) (the "Periodic Filing Rule"), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"), and that the Company has also cured the deficiency under Nasdaq Listing Rule 5620(a) (the "Annual Meeting Rule"), which requires listed companies to hold an annual meeting of stockholders during each fiscal year. The Company filed its Quarterly Reports on Form 10-Q for the quarterly periods ended August 27, 2023, November 29, 2023, and February 25, 2024 with the SEC on August 8, 2024, bringing the Company into compliance with the Periodic Filing Rule, and timely filed its Annual Report on Form 10-K for the year ended May 26, 2024 with the SEC on August 26, 2024. In addition, the Company held is 2024 annual meeting of stockholders on August 15, 2024. With the Company in compliance with the Periodic Filing Rule and having cured its deficiency under the Annual Meeting Rule, Nasdaq has ceased any action to delist the Company's common stock. While the Company is now in compliance with the Periodic Filing Rule, Nasdaq has informed the Company that it will be subject to a Mandatory Panel Monitor until September 4, 2025. If, within the monitoring period, the Company again fails to comply with the Periodic Filing Rule, the Company will not be permitted to provide the Nasdaq Staff with a plan of compliance with respect to that deficiency, nor will the Company be afforded a cure period. Instead, upon the Nasdaq Staff issuing a delist determination letter, the Company would then have an opportunity to request a new hearing with the initial Hearing Panel or a newly convened Hearing Panel if the initial Hearing Panel is unavailable. SIGNATURE Pursuant to the requirements